DEFA14A: Alcon to Acquire LENSAR in $14.00 Per Share Deal Plus Contingent Value Right

Alcon, a global leader in eye care, intends to acquire LENSAR, a move announced to LENSAR employees on March 24, 2025, with the transaction expected to close in mid-to-late 2025.

Summary

• Alcon intends to acquire LENSAR for $14.00 per share in cash, plus one contingent value right (CVR) per share.
• The deal is subject to customary closing conditions, including regulatory and stockholder approval, and is expected to close in mid-to-late 2025.
• Each CVR entitles the holder to receive $2.75 in cash if Alcon achieves 614,000 cumulative global cataract procedures using the LENSAR Laser System and ALLY Robotic Cataract Laser System between January 1, 2026, and December 31, 2027.
• LENSAR stock options, RSUs, and PSUs will be canceled and converted into the right to receive cash payments and CVRs.
• Until the deal closes, Alcon and LENSAR will continue to operate independently.
• A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed merger.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the acquisition providing liquidity for shareholders and potential for future value through the CVR. However, there are risks associated with the deal closing and achieving the milestone.

Positives

• LENSAR stockholders will receive $14.00 per share in cash upon closing of the acquisition.
• Stockholders have the potential to receive an additional $2.75 per share via the Contingent Value Right (CVR) if Alcon meets the specified milestone.
• The acquisition provides liquidity for LENSAR shareholders.
• The acquisition by Alcon, a global leader in eye care, could provide LENSAR's technology with broader market access and resources.

Negatives

• The deal is subject to customary closing conditions, including regulatory and stockholder approval, which introduces uncertainty.
• The CVR payment is contingent on Alcon achieving a specific milestone, which may not be met.
• LENSAR stock options, RSUs, and PSUs will be canceled, which may have tax implications for employees.
• Employees who voluntarily resign prior to the closing of the transaction may forfeit unvested equity awards.

Risks

• The proposed merger may not be completed in a timely manner or at all.
• Required regulatory approvals may not be obtained, may be delayed, or may be subject to unanticipated conditions.
• LENSAR's stockholders may not approve the merger.
• Competing offers or acquisition proposals for LENSAR may be made.
• The milestone related to the contingent value rights may not be achieved.
• The announcement or pendency of the merger may affect LENSAR's ability to retain and hire key personnel.
• Legal proceedings may be instituted against LENSAR following the announcement of the merger.
• LENSAR's stock price may decline significantly if the merger is not consummated.

Future Outlook

The transaction is expected to close in mid-to-late 2025, subject to customary closing conditions, including regulatory approvals and stockholder approval. Alcon and LENSAR will continue to operate independently until the deal closes.

Management Comments

• Im excited to announce that we have entered into an agreement through which Alcon, the global leader in eye care, intends to acquire LENSAR.
• Our goal is to make this transition as seamless as possible for you and your customers.

Industry Context

This acquisition reflects a trend of consolidation in the eye care industry, with larger players like Alcon seeking to expand their product portfolios and market reach through strategic acquisitions of innovative companies like LENSAR.

Comparison to Industry Standards

• The acquisition price of $14.00 per share plus a CVR is within the typical range for acquisitions of medical device companies with innovative technologies.
• Comparable acquisitions in the medical device space often include contingent value rights tied to the achievement of specific milestones, reflecting the inherent uncertainty in the adoption and market penetration of new technologies.
• The milestone of 614,000 cumulative global cataract procedures using LENSAR and ALLY systems is an ambitious target, reflecting Alcon's confidence in the potential of these technologies.
• Other companies in the cataract surgery market include Johnson & Johnson Vision, Carl Zeiss Meditec, and Bausch + Lomb.

Stakeholder Impact

• Shareholders will receive cash and a potential CVR payment.
• Employees face uncertainty regarding their roles and equity awards post-acquisition.
• Customers are assured of business as usual until the deal closes.
• Suppliers may experience changes in their relationships with the combined company.

Next Steps

• LENSAR will file a proxy statement with the SEC.
• A special stockholder meeting will be held to vote on the proposed merger.
• Regulatory approvals will be sought.
• Alcon and LENSAR will continue to operate independently until the deal closes.

Key Dates

Keywords

acquisition, LENSAR, Alcon, merger, stockholders, CVR, contingent value right, cataract procedures, ALLY, stock options, RSUs, PSUs